Colorectal Cancer

P=N/A, N=2000, Not yet recruiting, LanZhou University | Initiation date: Jan 2026 --> Jul 2026

The authors were unable to adequately address these concerns, noting that, due to the time elapsed since the original publication, retrieval of the underlying raw data for verification would be difficult. The authors therefore requested the retraction of the article.

It summarizes the molecular pathway networks regulated by these representative alkaloids and discusses their potential clinical benefits and current limitations.Building on this foundation, this paper further outlines future research directions, including structure optimization based on molecular structure considerations, targeted drug design strategies, and the prospects of alkaloid nanodelivery systems in clinical translation. The aim is to establish a systematic research framework for alkaloid-based colorectal cancer therapy and provide a theoretical basis for developing novel high-efficiency, low-toxicity treatment strategies.

This is the first report of concurrent miR-32 upregulation and PTEN downregulation in both CRC tissue and plasma. MiR-32 may represent a potential non-invasive biomarker candidate for CRC detection and disease stratification. However, these findings are observational and require validation in larger, multicenter cohorts and functional studies before clinical application.

We established a novel, clinically relevant CRLM risk stratification model with strong diagnostic and prognostic potential. By identifying pre-existing malignant features and stage-specific therapeutic vulnerabilities within the primary tumor, this model bridges the gap between biological discovery and precision medicine in advanced colorectal cancer.

Our investigation demonstrated that SH003 served as a novel CRC immunotherapy by the dual targeting of adaptive and innate checkpoints, PD-L1/CD47 via the regulation of c-Myc signaling, highlighting that SH003 may be an effective herbal candidate drug for the treatment of CRC.

Our study reveals SMOX as a critical driver of CRC progression and metastasis through ROS-mediated TRIB3 induction and subsequent Wnt/β-catenin activation, under the upstream regulation of ZNF263. This signaling axis provides new mechanistic insights and highlights SMOX/TRIB3 as promising therapeutic targets in CRC.

Raising physician awareness, as reflected by the untested rate, is a crucial factor in conducting clinical trials to implement perioperative cancer genomic medicine.

P=N/A, N=1200, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Initiation date: Jan 2026 --> Jul 2026

P1/2, N=111, Not yet recruiting, VM Discovery, Inc.

P=N/A, N=0, Withdrawn, University of Colorado, Denver | N=200 --> 0 | Not yet recruiting --> Withdrawn

Importantly, machine-learning models integrating individual amino acid levels with network-derived features significantly improved the prediction of recurrence or metastasis compared with models using either feature type alone and outperformed conventional biomarker carcinoembryonic antigen (AUROC = 0.806). These findings highlight the remodeling of circulating amino acid network as a promising strategy for prognostic stratification and postoperative monitoring in CRC.